Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2026-02-10 Regulatory Filings
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release announcing the treatment of the first patient in a clinical trial (REVISE) for a gene therapy candidate (GS010/LUMEVOQ). It details the partnership between a hospital and a biopharmaceutical company, the regulatory status of the trial, and the medical context of the disease. As it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is not a report publication announcement, it falls under the general regulatory filing category for corporate announcements.
2026-02-10 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release announcing the results of an Extraordinary General Meeting (Assemblée Générale Extraordinaire) held on January 28, 2026. It explicitly details the approval and rejection of specific resolutions voted on by shareholders. According to the filing definitions, documents detailing the official results of shareholder votes at a general meeting are classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-01-29 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release announcing the results of an Extraordinary General Meeting (EGM). It explicitly details the approval and rejection of specific resolutions voted on by shareholders. This falls directly under the definition of a Declaration of Voting Results.
2026-01-29 English
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds). It details that Heights Capital Management, Inc. has crossed the 5% ownership threshold in GENSIGHT BIOLOGICS S.A. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2026-01-20 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is a press release from GenSight Biologics titled 'GenSight Biologics publie sa situation de trésorerie au 31 décembre 2025 et fait un point sur son activité'. It provides a summary of the company's cash position, recent financing activities (capital increase), and operational updates (clinical trials and manufacturing). This is a periodic update on financial status and business operations, which fits the definition of an Earnings Release (ER) or a general management update on financial results. Given the focus on cash position and business outlook, it is classified as an Earnings Release. FY 2025
2026-01-08 French
Inside Information / News release on accounts, results
Capital/Financing Update Classification · 95% confidence The document is a press release from GenSight Biologics detailing its cash position as of December 31, 2025, and providing business updates regarding clinical trials and financing. While it mentions financial figures, it is not a full quarterly or annual report (10-K or IR), but rather an initial announcement of financial highlights and operational status. It fits the definition of an Earnings Release (ER) as it provides key financial highlights (cash position) and business updates for a specific period.
2026-01-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.